Genprex Inc
Change company Symbol lookup
Select an option...
GNPX Genprex Inc
ADDYY adidas AG
F Ford Motor Co
CCL Carnival Corp
BAC Bank of America Corp
AYTU Aytu BioScience Inc
AMD Advanced Micro Devices Inc
AAL American Airlines Group Inc
CREE Cree Inc
GILT Gilat Satellite Networks Ltd
Go

Health Care : Biotechnology |
Company profile

Genprex, Inc. is a clinical stage gene therapy company. The Company is focused on developing cancer-based upon its novel proprietary technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. The Company’s Oncoprex is lead product candidate, is the subject of an ongoing Phase I/II clinical trials at The University of Texas MD Anderson Cancer Center in patients with late stage non-small cell lung cancer, or NSCLC. Oncoprex gene therapy platform may also be effective with respect to other types of cancer, including breast, head and neck, renal cell (kidney), soft tissue cancer. The Company’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The Company’s Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis.

Price
Delayed
$2.27
Day's Change
-0.15 (-6.20%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.42
Day's Low
2.15
Volume
(Light)

Today's volume of 272,280 shares is on pace to be much lighter than GNPX's 10-day average volume of 1,872,607 shares.

272,280

Display:

Providers:

UpdateCancel
7 providers
March 24, 2020
Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders

Genprex, Inc. ("Genprex" or the "Company") (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its...(BusinessWire)

March 23, 2020
Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives

Genprex, Inc. ("Genprex" or the "Company") (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Catherine M. Vaczy as...(BusinessWire)

March 05, 2020
Lead Researcher Behind Genprex's Diabetes Gene Therapy Featured in New Video Interview

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced that Dr. George Gittes, the lead...(BusinessWire)

March 04, 2020
Genprex to Present at the 2020 LD Micro Virtual Conference

AUSTIN, TX & CAMBRIDGE, MA / ACCESSWIRE / March 4, 2020 / Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases...(Accesswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.